Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Revatis SA currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct art unit and 1 distinct examiner, reflecting a highly concentrated prosecution landscape for the company's current filings. By operating within a single art unit, the applicant can maintain a consistent technical narrative and legal strategy without the need to reconcile conflicting feedback from different review groups.
The busiest examiner for the portfolio is O'NEILL, MARISOL ANN, who is responsible for 1 pending office action. As the only examiner assigned to the current pending workload, their specific review style and interpretation of the prior art are the most critical factors for the applicant to consider. Practitioners should analyze the examiner's historical allowance rates and common rejection types within the Biotechnology & Pharmaceuticals sector. This insight can help in drafting a more targeted response that addresses the examiner's specific concerns and moves the application toward a successful conclusion.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O'NEILL, MARISOL ANN | 1 | 54.5% | +68.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800719 | CULTURING OF STEM CELLS | O'NEILL, MARISOL ANN | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17800719 | CULTURING OF STEM CELLS | O'NEILL, MARISOL ANN | 1633 | §103 | Non-Final OA | — | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRevatis SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marisol Ann O'Neill has the most, with 1 of Revatis SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
